Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of advanced unresectable or
             metastatic solid malignancy

          -  Positive biomarker results from a Clinical Laboratory Improvement Amendments
             (CLIA)-certified or equivalently accredited diagnostic laboratory and availability of
             a full report of the testing results. This may be from a tissue or blood sample.

          -  Evaluable or measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

          -  Life expectancy ≥8 weeks

          -  Adequate hematologic and end-organ function, as defined in the protocol, obtained
             within 14 days prior to initiation of study treatment

          -  Agrees to take measures to prevent pregnancy in the patient or partner

          -  In addition to the general inclusion criteria above, there are treatment-specific
             inclusion criteria that apply for each respective treatment arm (as detailed in the
             protocol)

        Exclusion Criteria:

          -  Current participation or enrollment in another therapeutic clinical trial

          -  Symptomatic or actively progressing CNS metastases (asymptomatic patients with treated
             or untreated CNS metastases may be eligible, provided all protocol-defined criteria
             are met)

          -  History of leptomeningeal disease, unless noted otherwise for a specific treatment arm
             of the study

          -  Whole brain radiotherapy within 14 days prior to start of study treatment

          -  Stereotactic radiosurgery within 7 days prior to start of study treatment

          -  Severe infection within 4 weeks prior to initiation of study treatment, including, but
             not limited to, hospitalization for complications of infections, or any active
             infection that, in the opinion of the investigator, could impact patient safety

          -  Receipt of any anticancer drug/biologic or investigational treatment 21 days prior to
             Cycle 1, Day 1 except hormone therapy, which can be given up to 7 days prior to Cycle
             1, Day 1 (androgen blockage may be continued for male patients with prostate cancer)

          -  Known HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV) infection with status
             outside of study-allowed criteria

          -  History of or concurrent serious medical condition or abnormality in clinical
             laboratory tests that precludes the patient's safe participation in and completion of
             the study or confounds the ability to interpret data from the study

          -  History of malignancy other than disease under study within 3 years prior to
             screening, with the exception of malignancies with a negligible risk of metastasis or
             death

          -  Incomplete recovery from any surgery prior to the start of study treatment that would
             interfere with the determination of safety or efficacy of study treatment

          -  Major surgical procedure, other than for diagnosis, or significant traumatic injury
             within 4 weeks prior to initiation of study treatment, or anticipation of need for a
             major surgical procedure during the study

          -  Significant cardiovascular disease, such as New York Heart Association cardiac disease
             (Class II or higher), myocardial infarction, or cerebrovascular accident within 3
             months prior to enrollment, unstable arrhythmias, or unstable angina

          -  Pregnant or breastfeeding, or intending to become pregnant during the study

          -  In addition to the general exclusion criteria above, there are treatment-specific
             exclusion criteria that apply for each respective treatment arm (as detailed in the
             protocol)